share_log

Earnings Call Summary | National Research(NRC.US) Q1 2024 Earnings Conference

Earnings Call Summary | National Research(NRC.US) Q1 2024 Earnings Conference

業績電話會議摘要 | 國家研究 (NRC.US) 2024 年第一季度業績會議
富途資訊 ·  05/11 22:39  · 電話會議

The following is a summary of the National Research Corporation (NRC) Q1 2024 Earnings Call Transcript:

以下是美國國家研究公司(NRC)2024年第一季度業績電話會議記錄的摘要:

Financial Performance:

財務業績:

  • National Research Corporation's financial results for Q1 2024 were consistent with expectations and showed no significant year-over-year changes.

  • The company's net debt stands at approximately $40 million.

  • They have a robust financial capacity with $23 million available on their line of credit and another $56 million available under the delayed draw term loan facility.

  • There was a marked increase in Operating cash flows to $12 million, up from $8 million the previous year.

  • 國家研究公司2024年第一季度的財務業績與預期一致,沒有顯著的同比變化。

  • 該公司的淨負債約爲4000萬美元。

  • 他們擁有強大的財務能力,可用的信貸額度爲2300萬美元,延遲提取定期貸款機制下還有5,600萬美元的可用信貸額度。

  • 運營現金流從去年的800萬美元顯著增加到1200萬美元。

Business Progress:

業務進展:

  • National Research Corporation is focused on doubling its total addressable market through portfolio additions, acquisitions, and partnerships.

  • They envision driving double-digit annual revenue growth, enhancing margins, and providing substantial value to investors.

  • They plan to introduce AI-enhanced, healthcare-specific solutions later this year.

  • The expansion of their sales force is in the pipeline, with significant hiring expected over the coming two to three years.

  • Organizational changes have been enacted, with new leadership roles, sales associates, and a technology team restructure.

  • They have shown a commitment to investment and shareholder value, spending $4 million on innovation and growth and returning $18 million to stockholders through dividends and stock repurchases.

  • National Research Corporation致力於通過投資組合的增加、收購和合作夥伴關係將其總潛在市場翻一番。

  • 他們設想推動兩位數的年收入增長,提高利潤率,併爲投資者提供可觀的價值。

  • 他們計劃在今年晚些時候推出人工智能增強的、針對醫療保健的解決方案。

  • 他們的銷售隊伍正在擴張中,預計在未來兩到三年內將有大量招聘人才。

  • 已經實施了組織變革,包括新的領導職位、銷售人員和技術團隊的重組。

  • 他們表現出了對投資和股東價值的承諾,在創新和增長上花費了400萬美元,並通過分紅和股票回購向股東返還了1800萬美元。

More details: National Research IR

更多詳情: 國家研究IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論